Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 14Carboplatin 12Specimen Handling 10sacituzumab govitecan 6Magnetic Resonance Spectroscopy 6Capecitabine 6Biopsy 6Paclitaxel 5Gemcitabine 5Nivolumab 4Cyclophosphamide 4olaparib 3Taxes 3Fulvestrant 3Cisplatin 3130-nm albumin-bound paclitaxel 3fludarabine 2durvalumab 2atezolizumab 2aldesleukin 2Platinum 2Letrozole 2Immunoglobulin G 2Epirubicin 2Albumin-Bound Paclitaxel 2zimberelimab 1vistusertib 1veliparib 1tremelimumab 1trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × CLR1404 × 30 days × Clear all
NCT07311993 2026-06-03

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

Cellectar Biosciences, Inc.

Phase 1 Recruiting
60 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡